F. Hoffmann-La Roche Ltd. manufactures pharmaceutical products. It offers pharmaceutical drugs, pharmaceutical instruments, and diagnostics solutions. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Mercy Bioanalytics, Inc. is an American company located in Natick, MA, that develops cancer detection products. It was founded in 2018 by Paul W. Blavin and Joseph Sedlak. Dawn R. Mattoon has been the CEO since 2022.\nThe company says this about itself: Mercy BioAnalytics, Inc. is on a mission to relieve suffering and save lives through the early detection of cancer. Early-stage cancer is difficult to detect, but when found, is more often amenable to curative therapy. The patented Mercy Halo™ liquid biopsy platform utilizes biomarker co-localization to interrogate highly abundant blood-based extracellular vesicles that carry unique cancer signatures from their parent cells. The Mercy Halo™ platform is designed to detect stage I cancer, when it is most treatable, and enhance the quality of life for cancer patients and their families. Mercy’s initial focus is the early detection of ovarian and lung cancers. Ovarian cancer, the most lethal gynecological cancer, typically goes undetected until it is too late to cure. Lung cancer, the number-one cancer killer, takes more lives than breast, prostate, and colorectal cancers combined.

ChemoCentryxis a biopharmaceutical company developing new medications targeted at inflammatory and autoimmune diseases and cancer. ChemoCentryx focuses on the discovery, development, and commercialization of orally-administered small molecule therapeutics that target chemokine receptors and related chemo-attractant receptors. The company's small molecule product candidates are designed to target a specific chemokine or chemo-attractant receptor, thereby blocking the inappropriate immune system cascade underlying a given disease.

BioPheresis Technologies, Inc. develops technology and medical devices for the treatment of cancer. The company was founded by M. Rigdon Lentz in 1995 and is headquartered in Atlanta, GA.

Pharmaco-Kinesis Corporation is a medical device company that aims to optimize the healing of the human body through proprietary local Smart Drug Delivery Systems™ (SDDS) and associated advanced devices to measure biological responses. Its product, Metronomic Biofeedback Pump™ (MBP) is a potentially revolutionary implantable infusion pump for local drug delivery that uses advanced microfluidic, diagnostic, and control mechanisms to deliver a variable, remotely programmable, a metronomic combination of tumor-fighting medications. The company was founded in 2006 and is headquartered in Inglewood, California.

Since our founding in May 1998 we have been focused on the impact of cortisol and the potential benefits of developing glucocorticoid receptor antagonists. About 80 percent of the tissues in the body have receptors for cortisol, and the effects of excess cortisol are severe and often life-threatening. Our initial research has been with mifepristone, which potently blocks the cortisol receptor. On February 17, 2012, the FDA approved Korlym® (mifepristone) in the United States as a once-daily oral medication for treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. Mifepristone is also being studied in a phase 3 trial, evaluating the impact of cortisol blockade on the psychotic features of psychotic depression. We plan to continue enrolling patients in this study throughout 2013.

Morphogenesis, Inc. develops targeted immunotherapies research. It focuses on the development of cell and gene therapies for the treatment of cancer. The company was founded by Patricia Lawman and Michael Lawman in 1990 and is headquartered in Tampa, FL.

Moerae Matrix is a privately held biopharmaceutical company focused on the development of first-in-class targeted therapeutics for fibrotic diseases.

Io Therapeutics, Inc. is a company headquartered in Spring, TX, that develops retinoid and rexinoid molecule drugs for treatment of cancer. It was founded by Martin E. Sanders and Rosh Chandraratna. Martin E. Sanders is the current CEO, occupying that position since 2011.

UAB Research Foundation (doing business as UABRF), a subsidiary of The University of Alabama System, is a company headquartered in Birmingham, AL. The firm engages in identify, assess, and market commercially viable technology developed at The University of Alabama at Birmingham.

EXINI Diagnostics provides advanced software for image analysis, targeted towards prostate cancer. EXINI’s technology was developed using unique image analysis derived from expert knowledge in medicine, image analysis, handling of large databases, and artificial neural networks.

Develops vaccines

BCN Biosciences is developing novel drugs in oncology as well as for the protection of normal tissues from radiation damage. They are committed to improving cancer treatment and diagnosis. The company manufactures innovative and effective medicines to treat cancer, one of the most serious diseases, with a team of experts in both drug discovery and oncology.

Fischer Medical is a leading medical device manufacturer located in Wheat Ridge, CO. Fischer Medical is the successor company to Fischer Imaging Corporation, which was a leading manufacturer of medical imaging equipment in the United States. Fischer Imaging Co. pioneered stereotactic needle biopsy under digital mammography guidance and developed one of the first Full Field Digital Mammography (FFDM) systems. Fischer Imaging Co. sold over $1B in x-ray systems, with over $400M to OEM partners such as GE Healthcare , Varian, Dornier, Philips, Kodak and Storz. In 1992, Fischer Imaging acquired Bloom Associates, Ltd. from Murray Bloom. Fischer has manufactured and serviced the Bloom stimulator ever since. Today, the same team continues to provide the highest level of quality and support.

Cetus Corporation was one of the first biotechnology companies. It was established in Berkeley, California in 1971, but conducted most of its operations in nearby Emeryville. Before merging with another company in 1991, it developed several significant pharmaceutical drugs as well as a revolutionary DNA amplification technique.

Leadiant Biosciences SA is a private company headquartered in Bern, Switzerland, that engages in conducting biotechnological research.